Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review.

Autor:	Susilo H; Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga Surabaya, Indonesia.; Department of Cardiology and Vascular Medicine, Universitas Airlangga Hospital Surabaya, Indonesia., Aldian FM; Faculty of Medicine, Universitas Airlangga Surabaya, Indonesia., Wungu CDK; Department of Physiology and Medical Biochemistry, Faculty of Medicine, Universitas Airlangga Surabaya, Indonesia.; Institute of Tropical Disease, Universitas Airlangga Surabaya, Indonesia., Alsagaff MY; Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga Surabaya, Indonesia.; Department of Cardiology and Vascular Medicine, Universitas Airlangga Hospital Surabaya, Indonesia., Sutanto H; Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga Surabaya, Indonesia., Multazam CECZ; National Heart and Lung Institute, Faculty of Medicine, Imperial College London London, UK.
Jazyk:	angličtina
Zdroj:	European cardiology [Eur Cardiol] 2024 Nov 12; Vol. 19, pp. e21. Date of Electronic Publication: 2024 Nov 12 (Print Publication: 2024).
DOI:	10.15420/ecr.2024.16
Abstrakt:	Cardiogenic shock (CS) is a critical condition with high mortality rate, as the current management of CS presents significant challenges. Exploration of more effective therapies is necessitated. This review article comprehensively examines the efficacy and safety of levosimendan in the management of CS. By synthesising evidence from numerous studies, a comparison of levosimendan over traditional inotropic agents, such as enoximone, dobutamine, dopamine and norepinephrine, is highlighted. The unique mechanism of action of levosimendan enhances myocardial contractility without increasing oxygen demand, offering a promising alternative for patients with CS. This review also delves into comparative studies that demonstrate the superiority of levosimendan in improving survival rates, haemodynamic parameters, and reducing the incidence of CS complications. Safety profiles and adverse effects are critically assessed to provide a balanced view of the therapeutic window provided by levosimendan. The review concludes that levosimendan is a valuable addition to the therapeutic strategy against CS, with the potential to improve patient outcomes. Competing Interests: Disclosure: The authors have no conflicts of interest to declare. Authors’ contributions: Conceptualisation: H Susilo, FMA, CDKW, MYA, H Sutanto; data curation: H Susilo, FMA; formal analysis: H Susilo, FMA, CECZM; investigation: H Susilo, FMA, CDKW, MYA, H Sutanto, CECZM; methodology: H Susilo, FMA, CDKW, MYA, H Sutanto; project administration: H Susilo; software: FMA; supervision: H Susilo, CDKW, MYA, H Sutanto; validation: H Susilo, CDKW, MYA, H Sutanto, CECZM; visualisation: FMA, CECZM; writing – original draft preparation: H Susilo, FMA, CDKW, MYA, H Sutanto, CECZM; writing – review & editing: H Susilo, FMA, CDKW, MYA, H Sutanto, CECZM. (Copyright © The Author(s), 2024. Published by Radcliffe Group Ltd.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu